INTERNATIONAL FLAVORS & FRAGRANCES INC
IFFAPI behind this page
IFF Q1 2026 request
Playground key active
/api/financials?ticker=IFF&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 2,741 | 2,843 | -3.6% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 839 | 796 | +5.4% |
| Health & Biosciences · Operating Segments | 595 | 540 | +10.2% |
| Scent · Operating Segments | 651 | 614 | +6.0% |
| Taste · Operating Segments | 656 | 627 | +4.6% |
Show Geography breakouts |
|||
| Asia | 656 | 670 | -2.1% |
| EMEA | 949 | 952 | -0.3% |
| Latin America | 348 | 353 | -1.4% |
| Net sales attributed to all foreign countries · Sales Revenue Net | 2,000 | 2,042 | -2.1% |
| North America | 788 | 868 | -9.2% |
| US · Sales Revenue Net | 741 | 801 | -7.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,741 | 2,843 | -3.6% |
| Cost of Revenue | 1,723 | 1,808 | -4.7% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 646 | 609 | +6.1% |
| Health & Biosciences · Operating Segments | 327 | 298 | +9.7% |
| Scent · Operating Segments | 375 | 344 | +9.0% |
| Taste · Operating Segments | 375 | 377 | -0.5% |
| Gross Profit | 1,018 | 1,035 | -1.6% |
| Research & Development | 166 | 164 | +1.2% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 14 | 12 | +16.7% |
| Health & Biosciences · Operating Segments | 55 | 52 | +5.8% |
| Scent · Operating Segments | 54 | 55 | -1.8% |
| Taste · Operating Segments | 43 | 40 | +7.5% |
| Selling, General & Administrative | 427 | 461 | -7.4% |
Show Business Segments breakouts |
|||
| Food Ingredients · Operating Segments | 99 | 92 | +7.6% |
| Health & Biosciences · Operating Segments | 92 | 81 | +13.6% |
| Scent · Operating Segments | 92 | 86 | +7.0% |
| Taste · Operating Segments | 101 | 94 | +7.4% |
| Operating Income | 273 | -903 | +130.2% |
| Interest Income | 3 | 4 | -25.0% |
| Other Non-Operating Income (Expense) | 13 | 20 | -35.0% |
| Income Before Taxes | 209 | -994 | +121.0% |
| Income Tax Expense (Benefit) | 39 | 23 | +69.6% |
| Net Income | 170 | -1,017 | +116.7% |
| Net Income | 169 | -1,018 | +116.6% |
| Comprehensive Income | 88 | -614 | +114.3% |
| EPS (Basic) | 0.66 | -3.98 | +116.6% |
| EPS (Diluted) | 0.66 | -3.98 | +116.6% |
| Wtd Avg Shares (Basic) | 256 | 256 | 0.0% |
| Wtd Avg Shares (Diluted) | 257 | 256 | +0.4% |
| Interest Expense | 44 | 71 | -38.0% |
| Net Income Loss Attributable To Noncontrolling Interest | 1 | 1 | 0.0% |
| Foreign Currency Transaction Gain Loss Before Tax | -16 | -24 | +33.3% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 562 | 613 | -8.3% |
| Inventory | 2,250 | 2,249 | 0.0% |
| Total Current Assets | 5,437 | 8,633 | -37.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,997 | 3,771 | +6.0% |
| Operating Lease Right-of-Use Assets | 572 | — | — |
| Goodwill | 8,220 | 8,030 | +2.4% |
Show Business Segments breakouts |
|||
| Health & Biosciences | 4,443 | 4,341 | +2.3% |
| Scent | 1,501 | 1,478 | +1.6% |
| Taste | 2,276 | 2,211 | +2.9% |
| Intangible Assets | 5,867 | 6,383 | -8.1% |
| Other Non-Current Assets | 1,051 | 869 | +20.9% |
| Total Assets | 25,144 | 28,265 | -11.0% |
| Current Liabilities | |||
| Accounts Payable | 1,371 | 1,325 | +3.5% |
| Commercial Paper | 154 | 292 | -47.3% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 154 | 292 | -47.3% |
| Estimate Of Fair Value Fair Value Disclosure | 154 | 292 | -47.3% |
| Current Portion of Long-Term Debt | -1,078 | -1,689 | +36.2% |
| Total Current Liabilities | 3,645 | 4,607 | -20.9% |
| Debt Current | 1,078 | 1,689 | -36.2% |
| Non-Current Liabilities | |||
| Long-Term Debt | 4,739 | 7,601 | -37.7% |
| Deferred Tax Liabilities | 1,353 | 1,543 | -12.3% |
| Other Non-Current Liabilities | 548 | 592 | -7.4% |
| Stockholders' Equity | |||
| Common Stock | 35 | 35 | 0.0% |
| Retained Earnings | -3,350 | -3,725 | +10.1% |
| Accumulated Other Comprehensive Income | -1,511 | -2,123 | +28.8% |
| Total Stockholders' Equity | 14,120 | 13,177 | +7.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -148 | -98 | -51.0% |
| Accumulated Other Comprehensive Income | -1,511 | -2,123 | +28.8% |
| Accumulated Translation Adjustment | -1,363 | -2,022 | +32.6% |
| Total Liabilities & Equity | 25,144 | 28,265 | -11.0% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 246 | 236 | +4.2% |
| Stock-Based Compensation | 16 | 19 | -15.8% |
| Deferred Income Taxes | -15 | -61 | +75.4% |
| Change in Accounts Receivable | -107 | -116 | +7.8% |
| Change in Inventory | -33 | -92 | +64.1% |
| Change in Accounts Payable | 176 | 154 | +14.3% |
| Net Cash from Operations | 257 | 127 | +102.4% |
| Investing Activities | |||
| Capital Expenditures | -165 | -179 | +7.8% |
| Net Cash from Investing | 23 | -157 | +114.6% |
| Financing Activities | |||
| Share Repurchases | 35 | — | — |
| Net Cash from Financing | -301 | 169 | -278.1% |
| Supplemental | |||
| Interest Paid | 28 | 37 | -24.3% |
| Unpaid Capital Expenditures | 97 | 58 | +67.2% |
| Other Cash Flow | |||
| Net Change in Cash | -28 | 179 | -115.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.